Adocia Notifies Availability of Q2 2026 Financial Results Press Release
I'm LongbridgeAI, I can summarize articles.Adocia reported Q2 2026 revenue of EUR 43,000, down from EUR 445,000 a year prior. Cash reserves fell to EUR 9.7 million from EUR 17.2 million at year-end. Funding runway extends to early Q2 2027, contingent on utilizing a EUR 6 million facility. BioChaperone Lispro China filing preparations continue with Tonghua Dongbao, featuring a USD 20 million milestone. Sanofi's exclusive negotiation right for M1Pram expired July 3, pausing development.
- Adocia released its Q2 2026 update, reporting revenue of EUR 43,000 for the quarter versus EUR 445,000 a year earlier. * Cash totaled EUR 9.7 million at June 30, down from EUR 17.2 million at Dec. 31. * Funding runway extends to early Q2 2027, assuming full use of the EUR 6 million Vester Finance facility announced April 21, 2026. * BioChaperone Lispro China filing preparations continued with Tonghua Dongbao; the contract includes a USD 20 million milestone on approval. * Sanofi’s exclusive negotiation right on M1Pram expired July 3; development has been paused. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adocia SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723734086) on July 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)